Epithelial to Mesenchymal Transition in a Clinical Perspective

Journal of Oncology

Volumn 2015, Issue , 2015, Pages

  Pasquier, Jennifer ^a,b   Abu Kaoud, Nadine ^a   Al Thani, Haya ^a,b   Rafii, Arash ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CANCER PROGNOSIS; DISEASE COURSE; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; REVIEW; TUMOR INVASION;

EID: 84942292057     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2015/792182     Document Type: Review

References (133)

1. C. L. Chaffer and R. A. Weinberg, "A perspective on cancer cell metastasis," Science, vol. 331, no. 6024, pp. 1559-1564, 2011.
2. T. J. Yeatman and G. L. Nicolson, "Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis," Seminars in Surgical Oncology, vol. 9, no. 3, pp. 256-263, 1993.
3. R. Kalluri and R. A. Weinberg, "The basics of epithelialmesenchymal transition," The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
4. K. Polyak and R. A. Weinberg, "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits," Nature Reviews Cancer, vol. 9, no. 4, pp. 265-273, 2009.
5. J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, "Epithelial-mesenchymal transitions in development and disease," Cell, vol. 139, no. 5, pp. 871-890, 2009.
6. L. Wan, K. Pantel, and Y. Kang, "Tumor metastasis: moving new biological insights into the clinic," Nature Medicine, vol. 19, no. 11, pp. 1450-1464, 2013.
7. D. C. Radisky, "Epithellial-mesenchymal transition," Journal of Cell Science, vol. 118, no. 19, pp. 4325-4326, 2005.
8. J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial-mesenchymal transitions," Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 131-142, 2006.
9. U. Cavallaro and G. Christofori, "Cell adhesion and signalling by cadherins and Ig-CAMs in cancer," Nature Reviews Cancer, vol. 4, no. 2, pp. 118-132, 2004.
10. B. M. Gumbiner, "Regulation of cadherin-mediated adhesion in morphogenesis," Nature Reviews Molecular Cell Biology, vol. 6, no. 8, pp. 622-634, 2005.
11. M. H. Chui, "Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step," International Journal of Cancer, vol. 132, no. 7, pp. 1487-1495, 2013.
12. K. Garber, "Epithelial-to-mesenchymal transition is important to metastasis, but questions remain," Journal of the National Cancer Institute, vol. 100, no. 4, pp. 232-239, 2008.
13. H. Ledford, "Cancer theory faces doubts," Nature, vol. 472, no. 7343, article 273, 2011.
14. D. Tarin, E. W. Thompson, and D. F. Newgreen, "The fallacy of epithelial mesenchymal transition in neoplasia," Cancer Research, vol. 65, no. 14, pp. 5996-6000, 2005.
15. S. Thomson, E. Buck, F. Petti et al., "Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition," Cancer Research, vol. 65, no. 20, pp. 9455-9462, 2005.
16. J. Zavadil, J. Haley, R. Kalluri, S. K. Muthuswamy, and E. Thompson, "Epithelial-mesenchymal transition," Cancer Research, vol. 68, no. 23, pp. 9574-9577, 2008.
17. J. H. Tsai and J. Yang, "Epithelial-mesenchymal plasticity in carcinoma metastasis," Genes and Development, vol. 27, no. 20, pp. 2192-2206, 2013.
18. J. P. Their, "Epithelial-mesenchymal transitions in tumor progression," Nature Reviews Cancer, vol. 2, no. 6, pp. 442-454, 2002.
19. B. D. Craene and G. Berx, "Regulatory networks defining EMT during cancer initiation and progression," Nature Reviews Cancer, vol. 13, no. 2, pp. 97-110, 2013.
20. H. Zheng and Y. Kang, "Multilayer control of the EMT master regulators," Oncogene, vol. 33, no. 14, pp. 1755-1763, 2014.
21. S. Lamouille, J. Xu, and R. Derynck, "Molecular mechanisms of epithelial-mesenchymal transition," Nature Reviews Molecular Cell Biology, vol. 15, no. 3, pp. 178-196, 2014.
22. C. Alix-Panabières, H. Schwarzenbach, and K. Pantel, "Circulating tumor cells and circulating tumor DNA," Annual Review of Medicine, vol. 63, pp. 199-215, 2012.
23. A. Rafii, F. Vidal, G. Rathat, and C. Alix-Panabières, "Circulating tumor cells: cornerstone of personalized medicine," Journal de Gynécologie Obstétrique et Biologie de la Reproduction, vol. 43, no. 9, pp. 640-648, 2014.
24. A. Bonnomet, L. Syne, A. Brysse et al., "Adynamic in vivomodel of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer," Oncogene, vol. 31, no. 33, pp. 3741-3753, 2012.
25. N. P. A. D. Gunasinghe, A. Wells, E. W. Thompson, and H. J. Hugo, "Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer," Cancer and Metastasis Reviews, vol. 31, no. 3-4, pp. 469-478, 2012.
26. D. Sarrió, S. M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, and J. Palacios, "Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype," Cancer Research, vol. 68, no. 4, pp. 989-997, 2008.
27. A. J. Trimboli, K. Fukino, A. de Bruin et al., "Direct evidence for epithelial-mesenchymal transitions in breast cancer," Cancer Research, vol. 68, no. 3, pp. 937-945, 2008.
28. M. Yu, A. Bardia, B. S. Wittner et al., "Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition," Science, vol. 339, no. 6119, pp. 580-584, 2013.
29. D. Entenberg, D. Kedrin, J. Wyckoff, E. Sahai, J. Condeelis, and J. E. Segall, "Imaging tumor cell movement in vivo," in Current Protocols in Cell Biology, chapter 19, unit 19. 7, 2013.
30. Y. Kang and K. Pantel, "Tumor cell dissemination: emerging biological insights from animal models and cancer patients," Cancer Cell, vol. 23, no. 5, pp. 573-581, 2013.
31. M. J. Blanco, G. Moreno-Bueno, D. Sarrio et al., "Correlation of Snail expression with histological grade and lymph node status in breast carcinomas," Oncogene, vol. 21, no. 20, pp. 3241-3246, 2002.
32. C. Côme, F. Magnino, F. Bibeau et al., "Snail and slug play distinct roles during breast carcinoma progression," Clinical Cancer Research, vol. 12, no. 18, pp. 5395-5402, 2006.
33. S. Elloul, M. B. Elstrand , J. M. Nesland et al., "Snail, slug, and smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma," Cancer, vol. 103, no. 8, pp. 1631-1643, 2005.
34. T. A. Martin, A. Goyal, G. Watkins, and W. G. Jiang, "Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer," Annals of Surgical Oncology, vol. 12, no. 6, pp. 488-496, 2005.
35. S. Elloul, I. Silins, C. G. Tropé, A. Benshushan, B. Davidson, and R. Reich, "Expression of E-cadherin transcriptional regulators in ovarian carcinoma," Virchows Archiv, vol. 449, no. 5, pp. 520-528, 2006.
36. T. Imai, A. Horiuchi, C. Wang et al., "Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells," The American Journal of Pathology, vol. 163, no. 4, pp. 1437-1447, 2003.
37. M.-Y. Cai, R.-Z. Luo, J.-W. Chen et al., "Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma," PLoS ONE, vol. 7, no. 2, Article ID e32838, 2012.
38. T. Li, Y. Zhu, W. Ren et al., "High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma," Medical Oncology, vol. 29, no. 4, pp. 2750-2761, 2012.
39. A. Miyoshi, Y. Kitajima, S. Kido et al., "Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma," British Journal of Cancer, vol. 92, no. 2, pp. 252-258, 2005.
40. K. Sugimachi, S. Tanaka, T. Kameyama et al., "Transcriptional repressor snail and progression of human hepatocellular carcinoma," Clinical Cancer Research, vol. 9, no. 7, pp. 2657-2664, 2003.
41. C. Kahlert, S. Lahes, P. Radhakrishnan et al., "Over expression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro," Clinical Cancer Research, vol. 17, no. 24, pp. 7654-7663, 2011.
42. C. Peña, J. M. Garciá, J. Silva et al., "E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations," Human Molecular Genetics, vol. 14, no. 22, pp. 3361-3370, 2005.
43. H. Wallerand , G. Robert, G. Pasticier et al., "The epithelialmesenchymal transition-inducing factor TWIST is an attractive target in advanced and /or metastatic bladder and prostate cancers," Urologic Oncology, vol. 28, no. 5, pp. 473-479, 2010.
44. S. D. da Silva, M. A. Alaoui-Jamali, F. A. Soares et al., "TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target," Cancer, vol. 120, no. 3, pp. 352-362, 2014.
45. S. Hosono, H. Kajiyama, M. Terauchi et al., "Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients," British Journal of Cancer, vol. 96, no. 2, pp. 314-320, 2007.
46. H. Kajiyama, S. Hosono, M. Terauchi et al., "Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary," Oncology, vol. 71, no. 5-6, pp. 394-401, 2007.
47. K. Shibata, H. Kajiyama, K. Ino et al., "Twist expression in patients with cervical cancer is associated with poor disease outcome," Annals of Oncology, vol. 19, no. 1, pp. 81-85, 2008.
48. A. Satelli and S. Li, "Vimentin in cancer and its potential as a molecular target for cancer therapy," Cellular and Molecular Life Sciences, vol. 68, no. 18, pp. 3033-3046, 2011.
49. P. C. Black, G. A. Brown, T. Inamoto et al., "Sensitivity to epidermal growth factor receptor inhibitor requires Ecadherin expression in urothelial carcinoma cells," Clinical Cancer Research, vol. 14, no. 5, pp. 1478-1486, 2008.
50. M. J. Kwon, J. H. Kwon, E. S. Nam et al., "TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma," Human Pathology, vol. 44, no. 9, pp. 1722-1729, 2013.
51. J. Kim, S. J. Hong, J. Y. Park et al., "Epithelial -mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma," Cancer Science, vol. 101, no. 6, pp. 1521-1528, 2010.
52. Y. Niwa, S. Yamada, M. Koike et al., "Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma," Journal of Surgical Oncology, vol. 110, no. 6, pp. 764-769, 2014.
53. S. Yamada, N. Okumura, L. Wei et al., "Epithelial tomesenchymal transition is associatedwith shorter disease-free survival in hepatocellular carcinoma," Annals of Surgical Oncology, vol. 21, no. 12, pp. 3882-3890, 2014.
54. X. Zhai, H. Zhu, W. Wang, S. Zhang, Y. Zhang, and G. Mao, "Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC," Medical Oncology, vol. 31, no. 6, article 970, 2014.
55. J. Zhao, D. Dong, L. Sun, G. Zhang, and L. Sun, "Prognostic significance of the epithelial-tomesenchymal transitionmarkers e-cadherin, vimentin and twist in bladder cancer," International Brazilian Journal of Urology, vol. 40, no. 2, pp. 179-189, 2014.
56. T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, and T. Kirchner, "Migrating cancer stem cells-an integrated concept of malignant tumour progression," Nature Reviews Cancer, vol. 5, no. 9, pp. 744-749, 2005.
57. G. Ghiaur, J. Gerber, and R. J. Jones, "Concise review: cancer stem cells and minimal residual disease," Stem Cells, vol. 30, no. 1, pp. 89-93, 2012.
58. J. Pasquier and A. Rafii, "Role of the microenvironment in ovarian cancer stem cell maintenance," BioMed Research International, vol. 2013, Article ID 630782, 10 pages, 2013.
59. W. Luo, S. Li, B. Peng, Y. Ye, X. Deng, and K. Yao, "Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma," PLoS ONE, vol. 8, no. 2, Article ID e56324, 2013.
60. H. S. Ryu, D. J. Park, H. H. Kim, W. H. Kim, and H. S. Lee, "Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer," Human Pathology, vol. 43, no. 4, pp. 520-528, 2012.
61. H. S. Ryu, J.-H. Chung, K. Lee et al., "Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma," Human Pathology, vol. 43, no. 12, pp. 2360-2370, 2012.
62. Y. Wang, S. Kim, and I. M. Kim, "Regulation of metastasis by microRNAs in ovarian cancer," Frontiers in Oncology, vol. 4, article 143, 2014.
63. S. F. Tavazoie, C. Alarcón, T. Oskarsson et al., "Endogenous human microRNAs that suppress breast cancer metastasis," Nature, vol. 451, no. 7175, pp. 147-152, 2008.
64. X. Fu, Y. Han, Y. Wu et al., "Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis," European Journal of Clinical Investigation, vol. 41, no. 11, pp. 1245-1253, 2011.
65. A. Rafii, C. Touboul, H. Al Thani, K. Suhre, and J. A. Malek, "Where cancer genomics should go next: a clinicians perspective," Human Molecular Genetics, vol. 23, no. R1, pp. R69-R75, 2014.
66. U. H. Frixen, J. Behrens, M. Sachs et al., "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells," The Journal of Cell Biology, vol. 113, no. 1, pp. 173-185, 1991.
67. J. Luo, D. M. Lubaroff, and M. J. C. Hendrix, "Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection," Cancer Research, vol. 59, no. 15, pp. 3552-3556, 1999.
68. S. E. Witta, R. M. Gemmill, F. R. Hirsch et al., "Restoring Ecadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines," Cancer Research, vol. 66, no. 2, pp. 944-950, 2006.
69. A. S. T. Wong and B. M. Gumbiner, "Adhesion-independent mechanism for suppression of tumor cell invasion by Ecadherin," The Journal of Cell Biology, vol. 161, no. 6, pp. 1191-1203, 2003.
70. M. Yanagisawa and P. Z. Anastasiadis, "p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness," Journal of Cell Biology, vol. 174, no. 7, pp. 1087-1096, 2006.
71. P. B. Gupta, T. T. Onder, G. Jiang et al., "Identification of selective inhibitors of cancer stem cells by high-throughput screening," Cell, vol. 138, no. 4, pp. 645-659, 2009.
72. B. Zhai, H.-X. Yan, S.-Q. Liu, L. Chen, M.-C. Wu, and H.-Y. Wang, "Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas," World Journal of Gastroenterology, vol. 14, no. 37, pp. 5665-5673, 2008.
73. Z.-Q. Ling, P. Li, M.-H. Ge et al., "Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer," International Journal of Molecular Medicine, vol. 27, no. 5, pp. 625-635, 2011.
74. I. Molina-Ortiz, R. A. Bartolomé, P. -Varas, G. P. Colo, and J. Teixidó, "Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA," The Journal of Biological Chemistry, vol. 284, no. 22, pp. 15147-15157, 2009.
75. G. Berx and F. Van Roy, "The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression," Breast Cancer Research, vol. 3, no. 5, pp. 289-293, 2001.
76. K. Strumane, G. Berx, and F. van Roy, "Cadherins in Cancer," in Cell Adhesion, vol. 165 of Hand book of Experimental Pharmacology, pp. 69-103, Springer, Berlin, Germany, 2004.
77. J. K. Field, "Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck," European Journal of Cancer Part B: Oral Oncology, vol. 28, no. 1, pp. 67-76, 1992.
78. B. Ruggeri, J. Caamano, T. J. Slaga, C. J. Conti, W. J. Nelson, and A. J. P. Klein-Szanto, "Alterations in the expression of uvomorulin and Na+, K(+)-adenosine triphosphatase during mouse skin tumor progression," TheAmerican Journal of Pathology, vol. 140, no. 5, pp. 1179-1185, 1992.
79. M. Köbel, D. Turbin, S. E. Kalloger, D. Gao, D. G. Huntsman, and C. B. Gilks, "Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites," International Journal of Gynecological Pathology, vol. 30, no. 4, pp. 366-371, 2011.
80. A. S. Wong, S. L. Maines-Bandiera, B. Rosen et al., "Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer," International Journal of Cancer, vol. 81, no. 2, pp. 180-188, 1999.
81. F. J. Rodriguez, L. J. Lewis-Tuffin, and P. Z. Anastasiadis, "E-cadherins dark side: possible role in tumor progression," Biochimica et Biophysica Acta, vol. 1826, no. 1, pp. 23-31, 2012.
82. T. Celià-Terrassa, O. Meca-Cortés, F. Mateo et al., "Epithelialmesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells," The Journal of Clinical Investigation, vol. 122, no. 5, pp. 1849-1868, 2012.
83. A. Gheldof and G. Berx, "Cadherins and epithelial-to-mesenchymal transition," Progress in Molecular Biology and Translational Science, vol. 116, pp. 317-336, 2013.
84. M. J. Wheelock, Y. Shintani, M. Maeda, Y. Fukumoto, and K. R. Johnson, "Cadherin switching," Journal of Cell Science, vol. 121, no. 6, pp. 727-735, 2008.
85. Y. Shintani, Y. Fukumoto, N. Chaika et al., "ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression," International Journal of Cancer, vol. 122, no. 1, pp. 71-77, 2008.
86. W.-W. Chang, F.-W. Hu, C.-C. Yu et al., "Quercetin in elimination of tumor initiating stem-like and mesenchymal transformation property in head and neck cancer," Head and Neck, vol. 35, no. 3, pp. 413-419, 2013.
87. N. M. Sadler, B. R. Harris, B. A. Metzger, and J. Kirshner, "Ncadherin impedes proliferation of themultiplemyeloma cancer stem cells," The American Journal of Blood Research, vol. 3, no. 4, pp. 271-285, 2013.
88. G. Lahat, Q.-S. Zhu, K.-L. Huang et al., "Vimentin is a novel anti-cancer therapeutic target; insights fromInVitro and InVivo mice xenograft studies," PLoS ONE, vol. 5, no. 4, Article ID e10105, 2010.
89. R. P. Singh, K. Raina, G. Sharma, and R. Agarwal, "Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice," Clinical Cancer Research, vol. 14, no. 23, pp. 7773-7780, 2008.
90. K. J. Wu, J. Zeng, G. D. Zhu et al., "Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression," Acta Pharmacologica Sinica, vol. 30, no. 8, pp. 1162-1168, 2009.
91. T.-T. Dong, H.-M. Zhou, L.-L. Wang, B. Feng, B. Lv, and M.-H. Zheng, "Salinomycin selectively targets CD133+ cell subpopulations and decreases malignant traits in colorectal cancer lines," Annals of Surgical Oncology, vol. 18, no. 6, pp. 1797-1804, 2011.
92. Y. Teng and X. Li, "The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms," Clinical and Experimental Metastasis, vol. 31, no. 3, pp. 367-377, 2014.
93. S.-P. Han, J.-H. Kim, M.-E. Han et al., "SNAI1 is involved in the proliferation and migration of glioblastoma cells," Cellular and Molecular Neurobiology, vol. 31, no. 3, pp. 489-496, 2011.
94. S. A. Mikheeva, A. M. Mikheev, A. Petit et al., "TWIST1 promotes invasion through mesenchymal change in human glioblastoma," Molecular Cancer, vol. 9, article 194, 2010.
95. M. Xia, M. Hu, J. Wang et al., "Identification of the role of Smad interacting protein 1 (SIP1) in glioma," Journal of Neuro-Oncology, vol. 97, no. 2, pp. 225-232, 2010.
96. M.-T. Chung, H.-C. Lai, H.-K. Sytwu et al., "SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway," Gynecologic Oncology, vol. 112, no. 3, pp. 646-653, 2009.
97. Y.-R. Na, S.-H. Seok, D.-J. Kim et al., "Bone morphogenetic protein 7 induces mesenchymal-to-epithelial transition in melanoma cells, leading to inhibition of metastasis," Cancer Science, vol. 100, no. 11, pp. 2218-2225, 2009.
98. T. Arumugam, V. Ramachandran, K. F. Fournier et al., "Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer," Cancer Research, vol. 69, no. 14, pp. 5820-5828, 2009.
99. W. Zhuo, Y. Wang, X. Zhuo, Y. Zhang, X. Ao, and Z. Chen, "Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway," Lung Cancer, vol. 62, no. 1, pp. 8-14, 2008.
100. W.-L. Zhuo, Y. Wang, X.-L. Zhuo, Y.-S. Zhang, and Z.-T. Chen, "Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway," Biochemical and Biophysical Research Communications, vol. 369, no. 4, pp. 1098-1102, 2008.
101. R. K. Srivastava, S.-N. Tang, W. Zhu, D. Meeker, and S. Shankar, "Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells," Frontiers in Bioscience, Elite, vol. 3, no. 2, pp. 515-528, 2011.
102. H.-C. Pai, L.-H. Chang, C.-Y. Peng et al., "Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibitionof Akt and Twist signalingpathway," Journal of Molecular Medicine, vol. 91, no. 3, pp. 347-356, 2013.
103. H.-Y. Hsu, T.-Y. Lin, P.-A. Hwang et al., "Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFbeta receptor degradation in breast cancer," Carcinogenesis, vol. 34, no. 4, pp. 874-884, 2013.
104. J. K. Myung, S. A. Choi, S. K. Kim, K. C. Wang, and S. H. Park, "Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition," International Journal of Clinical and Experimental Pathology, vol. 7, no. 5, pp. 1977-1987, 2014.
105. A. K. Reka, R. Kuick, H. Kurapati, T. J. Standiford, G. S. Omenn, and V. G. Keshamouni, "Identifying inhibitors of epithelialmesenchymal transition by connectivity map-based systems approach," Journal of Thoracic Oncology, vol. 6, no. 11, pp. 1784-1792, 2011.
106. K.-N. Chua, W.-J. Sim, V. Racine, S.-Y. Lee, B. C. Goh, and J. P. Thiery, "A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma," PLoS ONE, vol. 7, no. 3, Article ID e33183, 2012.
107. H. You, W. Ding, H. Dang, Y. Jiang, and C. B. Rountree, "c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma," Hepatology, vol. 54, no. 3, pp. 879-889, 2011.
108. O. O. Ogunwobi and C. Liu, "Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways," Clinical and Experimental Metastasis, vol. 28, no. 8, pp. 721-731, 2011.
109. Y. Guo, J. Xie, E. Rubin et al., "Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling," Cancer Research, vol. 68, no. 9, pp. 3350-3360, 2008.
110. H. Ikushima and K. Miyazono, "TGF? 2 signalling: a complex web in cancer progression," Nature Reviews Cancer, vol. 10, no. 6, pp. 415-424, 2010.
111. Y. Katsuno, S. Lamouille, and R. Derynck, "TGF-β signaling and epithelial-mesenchymal transition in cancer progression," Current Opinion in Oncology, vol. 25, no. 1, pp. 76-84, 2013.
112. J. Xu, S. Lamouille, and R. Derynck, "TGF-?-induced epithelial to mesenchymal transition," Cell Research, vol. 19, no. 2, pp. 156-172, 2009.
113. H. Peng, O. A. Carretero, N. Vuljaj et al., "Angiotensin-converting enzyme inhibitors: a new mechanism of action," Circulation, vol. 112, no. 16, pp. 2436-2445, 2005.
114. G. Subramanian, R. E. Schwarz, L. Higgins et al., "Targeting endogenous transforming growth factor β receptor signaling in Smad4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype," Cancer Research, vol. 64, no. 15, pp. 5200-5211, 2004.
115. C. Y. Park, D. K. Kim, and Y. Y. Sheen, "EW-7203, a novel small molecule inhibitor of transforming growth factor-beta (TGFbeta) type I receptor/activin receptor-like kinase-5, blocks TGF-beta1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells," Cancer Science, vol. 102, no. 10, pp. 1889-1896, 2011.
116. C.-Y. Park, J.-Y. Son, C. H. Jin, J.-S. Nam, D.-K. Kim, and Y. Y. Sheen, "EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung," European Journal of Cancer, vol. 47, no. 17, pp. 2642-2653, 2011.
117. Y. Y. Sheen, M.-J. Kim, S.-A. Park, S.-Y. Park, and J.-S. Nam, "Targeting the transforming growth factor-β signaling in cancer therapy," Biomolecules and Therapeutics, vol. 21, no. 5, pp. 323-331, 2013.
118. K. Duangkumpha, A. Techasen, W. Loilome et al., "BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma," Tumor Biology, vol. 35, no. 10, pp. 9667-9676, 2014.
119. A. R. Tan, G. Alexe, and M. Reiss, Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 453495, 2009.
120. L. Bueno, D. P. deAlwis, C. Pitou et al., "Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice," European Journal of Cancer, vol. 44, no. 1, pp. 142-150, 2008.
121. J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero, "Development of PI3K inhibitors: lessons learned from early clinical trials," Nature Reviews Clinical Oncology, vol. 10, no. 3, pp. 143-153, 2013.
122. F. Cappuzzo, T. Ciuleanu, L. Stelmakh et al., "Erlotinib asmaintenance treatment in advanced non-small-cell lung cancer: a multicentre, rand omised, placebo-controlled phase 3 study," The Lancet Oncology, vol. 11, no. 6, pp. 521-529, 2010.
123. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., "Erlotinib in previously treated non-small-cell lung cancer," The New England Journal of Medicine, vol. 353, no. 2, pp. 123-132, 2005.
124. S. E. Witta, R. M. Jotte, K. Konduri et al., "Rand omized phase II trial oferlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy," Journal of Clinical Oncology, vol. 30, no. 18, pp. 2248-2255, 2012.
125. J. C. Morris, A. R. Tan, T. E. Olencki et al., "Phase I study of GC1008 (Fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma," PLoS ONE, vol. 9, no. 3, Article ID e90353, 2014.
126. J. A. Malek, E. Mery, Y. A. Mahmoud et al., "Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis," PLoS ONE, vol. 6, no. 12, Article ID e28561, 2011.
127. R. Lis, J. Capdet, P. Mirshahi et al., "Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells," International Journal of Oncology, vol. 37, no. 6, pp. 1453-1461, 2010.
128. R. Lis, C. Touboul, N. M. Halabi et al., "Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile," Journal of Translational Medicine, vol. 12, article 59, 2014.
129. R. Lis, C. Touboul, C. M. Raynaud et al., "Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties," PLoS ONE, vol. 7, no. 5, Article ID e38340, 2012.
130. J. A. Malek, A. Martinez, E. Mery et al., "Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis," Journal of Translational Medicine, vol. 10, no. 1, article 121, 2012.
131. J. Pasquier, B. S. Guerrouahen, H. Al Thawadi et al., "Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubesmodulates chemoresistance," Journal of Translational Medicine, vol. 11, no. 1, article 94, 2013.
132. J. Pasquier, H. A. Thawadi, P. Ghiabi et al., "Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation," Cancer Microenvironment, vol. 7, no. 1-2, pp. 41-59, 2014.
133. C. Touboul, R. Lis, H. Al Farsi et al., "Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model," Journal of Translational Medicine, vol. 11, no. 1, article 28, 2013.